Update
$Travere Therapeutic(TVTX.US$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
